| Colectomy rates did not decrease in paediatric-and adult-onset ulcerative colitis during the biologics era: a nationwide study from the epi-IIRN O Atia, E Orlanski-Meyer, R Lujan, N Ledderman, S Greenfeld, R Kariv, ... Journal of Crohn's and Colitis 16 (5), 796-803, 2022 | 32 | 2022 |
| Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study O Atia, Z Shavit-Brunschwig, DR Mould, R Stein, M Matar, M Aloi, ... The Lancet Gastroenterology & Hepatology 8 (1), 31-42, 2023 | 25 | 2023 |
| Perianal Crohn’s disease is associated with poor disease outcome: a nationwide study from the epiIIRN cohort O Atia, N Asayag, G Focht, R Lujan, O Ledder, S Greenfeld, R Kariv, ... Clinical Gastroenterology and Hepatology 20 (3), e484-e495, 2022 | 20 | 2022 |
| Improved outcomes of paediatric and adult Crohn’s disease and association with emerging use of biologics–A nationwide study from the Epi-IIRN O Atia, E Orlanski-Meyer, R Lujan, N Ledderman, S Greenfeld, R Kariv, ... Journal of Crohn's and Colitis 16 (5), 778-785, 2022 | 17 | 2022 |
| Risk of cancer in paediatric onset inflammatory bowel diseases: a nation-wide study from the epi-IIRN O Atia, S Harel, N Ledderman, S Greenfeld, R Kariv, I Dotan, R Balicer, ... Journal of Crohn's and Colitis 16 (5), 786-795, 2022 | 17 | 2022 |
| Incidence, management, and outcomes of very early onset inflammatory bowel diseases and infantile-onset disease: an Epi-IIRN study O Atia, EI Benchimol, N Ledderman, S Greenfeld, R Kariv, YL Weisband, ... Clinical Gastroenterology and Hepatology 21 (10), 2639-2648. e6, 2023 | 14 | 2023 |
| 5‐aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease—A nationwide cohort study O Atia, I Goren, TS Fischler, YL Weisband, S Greenfeld, R Kariv, ... Alimentary Pharmacology & Therapeutics 57 (9), 1004-1013, 2023 | 13 | 2023 |
| Role of thiopurines in pediatric inflammatory bowel diseases: a real-life prospective cohort study O Atia, O Ledder, T Ben-Moshe, R Lev-Tzion, Y Rachmen, EO Meyer, ... Journal of Pediatric Gastroenterology and Nutrition 70 (6), 825-832, 2020 | 13 | 2020 |
| Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real‐world patient mix O Atia, G Pujol‐Muncunill, VM Navas‐López, E Orlanski‐Meyer, O Ledder, ... Alimentary pharmacology & therapeutics 56 (5), 794-801, 2022 | 11 | 2022 |
| Number of prior vaginal deliveries and trial of labor after cesarean success O Atia, R Rotem, O Reichman, A Jaffe, S Grisaru-Granovsky, HY Sela, ... European Journal of Obstetrics & Gynecology and Reproductive Biology 256 …, 2021 | 10 | 2021 |
| Sleep disorders in patients with primary ciliary dyskinesia, cystic fibrosis with and without pancreatic insufficiency M Cohen-Cymberknoh, O Atia, A Gileles-Hillel, E Kerem, J Reiter Respiratory Medicine 151, 96-101, 2019 | 10 | 2019 |
| Thiopurines have longer treatment durability than methotrexate in adults and children with Crohn’s disease: a nationwide analysis from the epi-IIRN cohort O Atia, C Friss, N Ledderman, S Greenfeld, R Kariv, S Daher, H Yanai, ... Journal of Crohn's and Colitis 17 (10), 1614-1623, 2023 | 7 | 2023 |
| Existing prediction models of disease course in paediatric Crohn’s disease are poorly replicated in a prospective inception cohort O Atia, B Kang, E Orlansky-Meyer, O Ledder, R Lev Tzion, S Choi, ... Journal of Crohn's and Colitis 16 (7), 1039-1048, 2022 | 7 | 2022 |
| Perianal Crohn disease is more common in children and is associated with complicated disease course despite higher utilization of biologics: a population-based study from the … O Atia, G Focht, R Lujan, O Ledder, S Greenfeld, R Kariv, I Dotan, H Yanai, ... Journal of Pediatric Gastroenterology and Nutrition 74 (6), 788-793, 2022 | 6 | 2022 |
| Prevalence and outcomes of no treatment versus 5-ASA in ulcerative colitis: a nationwide analysis from the epi-IIRN O Atia, R Magen Rimon, N Ledderman, S Greenfeld, R Kariv, ... Inflammatory Bowel Diseases 30 (2), 213-221, 2024 | 5 | 2024 |
| Durability of the first biologic in patients with Crohn’s disease: a nationwide study from the epi-IIRN O Atia, C Friss, G Focht, R Magen Rimon, N Ledderman, S Greenfeld, ... Journal of Crohn's and Colitis 18 (1), 38-46, 2024 | 5 | 2024 |
| Anosmia and dysgeusia amongst COVID‐19 patients are associated with low levels of serum glucagon‐like peptide 1 E Ben‐Chetrit, A Ben‐Ya'acov, A Quitina, O Atia, E Regev, E Shteyer, ... International Journal of Clinical Practice 75 (12), e14996, 2021 | 4 | 2021 |
| Development and validation of the IBD-REFER criteria: early referral for suspected inflammatory bowel diseases in adults and children O Atia, A Shosberger, G Focht, O Ledder, R Lev-Tzion, D Navon, A Assa, ... Crohn's & Colitis 360 2 (2), otaa027, 2020 | 4 | 2020 |
| Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort O Atia, RCW Klomberg, L de Ridder, P Kemos, FM Ruemmele, B Kang, ... Alimentary Pharmacology & Therapeutics 58 (2), 182-190, 2023 | 3 | 2023 |
| OP12 Does early initiation of biologics change the natural history of IBD? a nationwide study from the epi-IIRN G Focht, R Lujan, O Atia, S Greenfeld, R Kariv, Y Loewenberg Weisband, ... Journal of Crohn's and Colitis 17 (Supplement_1), i17-i18, 2023 | 3 | 2023 |
